Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 10, 2015, Pages 12333-12345

  Bai, Wenqi ^a   Wu, Yueqin ^a   Zhang, Ping ^a   Xi, Yanfeng ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; Chemotherapy efficacy; Colorectal cancer; Immunohistochemistry; Metabolic enzymes; QRT PCR

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; PRIMER DNA; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DNA PRIMERS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 85013226765     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Leung AM, Scharf AW, Vu HN. Factors affecting number of lymph nodes harvested in colorectal cancer. J Surg Res 2011; 168: 224-230.
2. Maindrault-Goebel F, Louvet C, André T, Carola E, Lotz JP, Molitor JL, Garcia ML, Gilles-Amar V, Izrael V, Krulik M, de Gramont A. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999; 35: 1338-1342.
3. Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet 2007; 370: 2020-2029.
4. Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR. An update on cancer-and chemotherpy-related cognitive dysfunction: current status. Semin Oncol 2011; 38: 431-438.
5. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Konishi T, Horie H, Ikeuchi H, Eshima K, Muto T. Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. Clin Transl Oncol 2011; 13: 419-425.
6. Nakajima T, Yasufuku K, Suzuki M, Hiroshima K, Nakatani Y, Fujisawa T, Yoshino I. Thymidylate synthase, dihydehydrogenase, thymidine phosphorylase, orotate phosphoribosyltransferase mRNA expression in lung cancer metastatic lymph node samples obtained by ultrasound-guided transbronchial needle aspiration: a pilot study. Clin Lung Cancer 2011; 12: 293-297.
7. Fromowitz FB, Viola MV, Chao S, Oravez S, Mishriki Y, Finkel G, Grimson R, Lundy J. Ras P2l expression in the progression of breast eancer. Hum Pathol 1987; 18: 1268-1275.
8. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood J, Wainscoat JS, Hatton CS. Microrna expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 2007; 121: 1156-1161.
9. -ΔΔCt Method. Method 2001; 25: 402-408.
10. Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, Adenis A, Faroux R, Rebischung C, Bergougnoux L, Kockler L, Douillard JY; GI Group of the French Anti-Cancer Centers. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOL-FOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 2011; 128: 682-690.
11. Jin C, Yao L, Long J, Fu DL, Yu XJ, Xu J, Yang F, Ni QX. Effect of multiple-phase regional infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. Chin Med J 2009; 122: 284-290.
12. Yao L, Itoh S, Furuta I. Thymidine phosphorylase expression in oal squamous cell carcinoma. Oral Oncol 2002; 38: 584-590.
13. Afzal S, Gusella M, Jensen SA, Vainer B, Vogel U, Andersen JT, Brødbæk K, Petersen M, Jimenez-Solem E, Adleff V, Budai B, Hitre E, Láng I, Orosz E, Bertolaso L, Barile C, Padrini R, Kralovánszky J, Pasini F, Poulsen HE. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. Pharmacogenomics 2011; 12: 1257-1267.
14. Muhale FA, Wetmore BA, Thomas RS, McLeod HL. Systems pharmacology assessment of the 5-fluorouracil pathway. Pharmacogenomics 2011; 12: 341-350.
15. Furuhata T, Kawakami M, Okita K, Kimura Y, Kihara C, Tsuruma T, Ohmura T, Yamaguchi K, Hata F, Katsuramaki T, Sasaki K, Hirata K. Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-Fluorouracil treated patients. J Exp Clin Cancer Res 2006; 25: 79-82.
16. Kumamoto K, Kuwabara K, Tajima Y, Amano K, Hatano S, Ohsawa T, Okada N, Ishibashi K, Haga N, Ishida H. Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capturemicrodissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with livermetastasis. Oncol Lett 2012; 3: 983-989.
17. Yoshimoto K, Kawahara H, Kobayashi S, Kashiwagi H, Hirai K, Yanaga K. Importance of thymidine phosphorylase expression at the invasive front of T3 rectal cancer as a prognostic factor. Dig Surg 2006; 23: 331-335.
18. Nakata B, Muguruma K, Yamagata S, Yukimoto K, Maeda K, Nishiguchi Y, Ohira M, Kato Y, Hirakawa K. Differences in dihydropyrimidine dehydrogenase activities between gastric and color ectal cancer. Dig Dis Sci 2004; 49: 60-64.
19. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Kashiwaba M, Oyama K, Takahashi M, Maesawa C, Saito K, Takechi T, Fukushima M. Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydroge nase mRNA level in gastric cancer by real-time RT-PCR. Jpn J Cancer Res 2002; 93: 1342.
20. Goto T, Shinmura K, Yokomizo K, Sakuraba K, Kitamura Y, Shirahata A, Saito M, Kigawa G, Nemoto H, Sanada Y, Hibi K. Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer. Anticancer Res 2012; 32: 1757.
21. Hu HB, Kuang L, Zeng XM, Li B, Liu EY, Zhong MZ. Predictive value of thymidylate synthase expression in gastric cancer: a systematic review with meta-analysis. Asian Pac J Cancer Prev 2012; 13: 261-267.
22. Tanaka K, Saigusa S, Toiyama Y, Koike Y, Okugawa Y, Yokoe T, Inoue Y, Kobayashi M, Miki C, Kusunoki M. TS and DPD mRNA levels on formalinfixed paraffin-embedded specimens as predictors for distant recurrence of rectal cancer treated with preoperative chemoradiotherapy. J Surg Oncol 2012; 105: 529-534.
23. Jeong SH, Han JH, Kim JH, Ahn MS, Hwang YH, Lee HW, Kang SY, Park JS, Choi JH, Lee KJ, Sheen SS, Lim HY. Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. Dig Dis Sci 2011; 56: 131-138.
24. Kim KH, Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, Jang JS, Kim MC, Kim SJ, Kim HJ. Clinicopathologic signifi cance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers 2011; 16: 74-82.
25. Tanaka K, Saigusa S, Toiyama Y, Koike Y, Okugawa Y, Yokoe T, Inoue Y, Kobayashi M, Miki C, Kusunoki M. TS and DPD mRNA levels on formalin-fixedparaffin-embedded specimens as predictors for distantrecurrence of cancer treated with preoperativechemora-diotherapy. J Surg Oncol 2012; 105: 529-534.
26. Bijnsdorp IV, Capriotti F, Kruyt FA, Losekoot N, Fukushima M, Griffioen AW, Thijssen VL, Peters GJ. Thymidine phosphorylase incancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors. Br J Cancer 2011; 104: 1185-1192.
27. Toi M, Atiqur Rahman M, Bando H, Chow LW. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biologyand Treatment. Lancet Oncol 2005; 6: 158-166.
28. Gustavsson B, Kaiser C, Carlsson G, Wettergren Y, Odin E, Lindskog EB, Niyikiza C, Ma D. Molecular determinants of efficacy for 5-FU based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. Int J Cancer 2009; 124: 1220-1226.
29. Sadahiro S, Suzuki T, Tanaka A, Okada K, Nagase H, Uchida J. Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response tooral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. Cancer Chemother Pharmacol 2012; 70: 285-291.
30. Yamada H, Iinuma H, Watanabe T. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy. Oncol Rep 2008; 19: 729-735.
31. Kuwabara K, Kumamoto K, Ishibashi K, Okada N, Ishiguro T, Ohsawa T, Haga N, Miura I, Ishida H. The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer. Gan To Kagaku Ryoho 2011; 38: 2224-2227.
32. Boskos CS, Liacos C, Korkolis D, Aygerinos K, Lamproglou I, Terpos E, Stoupa E, Baltatzis G, Beroukas K, Papasavvas P, Dimopoulos MA, Bamias A. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabin in patients with advanced rectal cancer. J Surg Oncol 2010; 102: 408-412.